Critical Contrast: Shanghai Junshi Biosciences (OTCMKTS:SHJBF) vs. Hyperion DeFi (NASDAQ:HYPD)

Hyperion DeFi (NASDAQ:HYPD) and Shanghai Junshi Biosciences (OTCMKTS:SHJBF) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Hyperion DeFi and Shanghai Junshi Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	1	2	2	0	2.20
Shanghai Junshi Biosciences	0	0	0	0	0.00

Hyperion DeFi currently has a consensus price target of $4.58, suggesting a potential upside of 38.89%. Given Hyperion DeFi’s stronger consensus rating and higher probable upside, equities analysts plainly believe Hyperion DeFi is more favorable than Shanghai Junshi Biosciences.

Insider and Institutional Ownership

25.8% of Hyperion DeFi shares are owned by institutional investors. 10.9% of Hyperion DeFi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Hyperion DeFi and Shanghai Junshi Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-119.59%	-68.88%
Shanghai Junshi Biosciences	N/A	N/A	N/A

Valuation & Earnings

This table compares Hyperion DeFi and Shanghai Junshi Biosciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$60,000.00	449.35	-$49.82 million	($4.04)	-0.82
Shanghai Junshi Biosciences	N/A	N/A	N/A	N/A	N/A

Shanghai Junshi Biosciences has lower revenue, but higher earnings than Hyperion DeFi.

Summary

Hyperion DeFi beats Shanghai Junshi Biosciences on 6 of the 8 factors compared between the two stocks.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

About Shanghai Junshi Biosciences

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.